Vivian Lee Lee Bishay

Dr. Vivian Lee Lee Bishay


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in European Journal of Radiology
Verified
Journal Article
Closed access
JLJ.D. Lavian
J.D. Lavian
LTL.M. Thornton
L.M. Thornton
AZA. Zybulewski
A. Zybulewski
EKE. Kim
E. Kim
SNS.F. Nowakowski
S.F. Nowakowski
VBVivian Lee Lee Bishay
Vivian Lee Lee Bishay

1 November 2025 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Open access
SBSripal Bangalore
Sripal Bangalore
RTR. Dana Tomalty
R. Dana Tomalty
HKHerman Kado
Herman Kado
SSSameh Sayfo
Sameh Sayfo
ARAdam Raskin
Adam Raskin
VBVivian Lee Lee Bishay
Vivian Lee Lee Bishay
BACKGROUND: Mechanical thrombectomy offers a promising alternative to thrombolytic-based approaches for reducing thrombus burden and right heart strain in acute pulmonary embolism. This pivotal Food and Drug Administration–approval trial evaluated the safety and efficacy of the Symphony Thrombectomy System (Imperative Care, Inc, Campbell, CA) in acute intermediate-risk pulmonary embolism. METHODS: Patients with intermediate-risk pulmonary embolism (systolic blood pressure ≥90 mm Hg; right ventricle-to-left ventricle ratio >0.9) were enrolled without roll-ins. The primary safety end point was the rate of major adverse events within 48 hours, defined as a composite of all-cause major bleeding, device-related mortality, and serious device-related events, adjudicated by an academic independent safety board. The primary efficacy end point was the core laboratory–assessed mean change in right ventricle-to-left ventricle ratio from baseline to 48 hours. Prespecified performance goals were set for both. Exploratory end points included immediate postprocedure change in mean pulmonary artery pressure and change in modified Miller index at 48 hours. Safety was assessed in the intention-to-treat cohort and efficacy in the modified intention-to-treat cohort, excluding patients receiving nonstudy device treatments. RESULTS: Between December 2023 and May 2025, 109 patients were treated at 17 US centers (intention-to-treat), with 106 in the modified intention-to-treat cohort. The major adverse events rate was 0.9% (1/109), with an upper 97.5% CI of 5.7%, meeting the <15% safety goal ( P 0.20 performance goal ( P <0.001). Mean pulmonary artery pressure decreased from 29.1±7.2 to 22.2±6.6 mm Hg (24%) and the modified Miller index from 24.2±4.1 to 14.9±5.4 (38%), both P <0.001. CONCLUSIONS: These data support the safety and effectiveness of the Symphony Thrombectomy System in patients with acute intermediate-risk pulmonary embolism. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06062329.

24 September 2021 in Expert Review of Medical Devices
Verified
Journal Article
Closed access
VBVivian Lee Lee Bishay
Vivian Lee Lee Bishay
OAOmosalewa Adenikinju
Omosalewa Adenikinju
RTRachel Todd
Rachel Todd
Introduction: Pulmonary embolism (PE) is the third leading cause of cardiovascular mortality. There has been little change in PE mortality rates over the past two decades making this an appealing area for innovation and development. Areas Covered: While anticoagulation (AC) and systemic thrombolysis (ST) are the mainstay treatments for high risk PE and intermediate-high risk PE with decompensation, advancements in catheter based therapies offer potential alternatives. Areas covered here will include present guidelines for PE treatment and the landscape of catheter-directed therapies with a focus on the FlowTriever (FT) Retrieval System. Available safety and efficacy data will be reviewed. An online search via Google Scholar and PubMed with the keywords INARI Flowtriever, venous thromboembolism, and pulmonary embolism, alongside bibliographies of published articles, was undertaken as a review of the literature on the FlowTriever system for this device overview. Expert opinion: The five year outlook on the role of catheter-directed therapies in the management of PE includes continued innovation in catheter directed therapies and a number of high quality trials on the horizon.

1 November 2014 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
VBVivian Lee Lee Bishay
Vivian Lee Lee Bishay
KMKatharine Maglione
Katharine Maglione
KLKaren Lee
Karen Lee
AFAaron Fischman
Aaron Fischman
RLRobert Lookstein
Robert Lookstein
RKRegina Khanna
Regina Khanna
Purpose: This study examines the safety and efficacy of transarterial chemoembolization using doxorubicin-loaded 30–60 µm QuadraSphere microspheres (DEM-TACE) for the treatment of hepatocellular carcinoma. Materials and methods: Over 10 weeks, patients with hepatocellular carcinoma. (Child–Pugh A/B: 65%/35%) were embolized with 30–60 µm QuadraSphere microspheres. Excluded patients had previous locoregional therapy, macrovascular invasion, extrahepatic disease, Child–Pugh score >B7, ECOG performance status >0, and total bilirubin >3 mg/dL. Technical success, minor and major complications, 30-day hospital readmission rate, and 30-day mortality were assessed. α-Fetoprotein levels before and after treatment were compared. Local response was evaluated by radiologic tumor response per modified Response Evaluation Criteria in Solid Tumors 1 month after treatment. Results: Thirty tumors (mean size, 2.3 cm; range, 1.0–4.9 cm) were treated in 20 patients (16 male and 4 female; mean age, 64.7 years). There were no major complications. Thirty-day mortality was 0%. Minor complications included postembolization syndrome in 16.7% of cases and transient rise in liver enzymes requiring no therapy. Mean a-fetoprotein levels trended down following treatment (71.8±201.9 ng/mL vs 53.4±116.7 ng/mL), but were not statistically significant. Complete response was achieved in 30% of patients, partial response in 35%, stable disease in 30%, and progression of disease in 5%. Overall objective response was 65%. Mean follow-up was 10.4 months (range, 2–16.4 months). Conclusion: DEM-TACE with doxorubicin-loaded 30–60 µm QuadraSpheres is feasible, well tolerated, and associated with promising tumor response in early and intermediate stage disease.

28 January 2023 in Clinical Imaging
Verified
Journal Article
Closed access
AMAriana C. Mills
Ariana C. Mills
DGDaryl T. Goldman
Daryl T. Goldman
BMBrett Marinelli
Brett Marinelli
JSJay Sanghvi
Jay Sanghvi
KGKirema Garcia-Reyes
Kirema Garcia-Reyes
VBVivian Lee Lee Bishay
Vivian Lee Lee Bishay

28 May 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
BOBurak Berksu Ozkara
Burak Berksu Ozkara
DBDavid Bamshad
David Bamshad
RGRamita Gowda
Ramita Gowda
MKMert Karabacak
Mert Karabacak
VBVivian Lee Lee Bishay
Vivian Lee Lee Bishay
AFAaron Fischman
Aaron Fischman
Background/Objectives: Prostatic artery embolization (PAE) has been increasingly recognized, especially with recent progress in embolization techniques for the management of lower urinary tract symptoms due to benign prostatic hyperplasia. Nevertheless, a proportion of patients undergoing PAE fail to demonstrate clinical improvement. Machine learning models have the potential to provide valuable prognostic insights for patients undergoing PAE. Methods: A retrospective cohort study was performed utilizing a modified prior-data fitted network architecture to predict short-term (7 weeks) favorable outcomes, defined as a reduction greater than 9 points in the International Prostate Symptom Score (IPSS), in patients who underwent PAE with nBCA glue. Patients were stratified into two groups based on the median IPSS reduction value, and a binary classification model was developed to predict the outcome of interest. The model was developed using clinical tabular data, including both pre-procedural and intra-procedural variables. SHapley Additive ExPlanations (SHAP) were used to uncover the relative importance of features. Results: The final cohort included 109 patients. The model achieved an accuracy of 0.676, an MCC of 0.363, a precision of 0.666, a recall of 0.856, an F1-score of 0.731, and a Brier score of 0.203, with an AUPRC of 0.851 and an AUROC of 0.821. SHAP analysis identified pre-PAE IPSS, prior therapy, right embolization volume, preoperative quality of life, and age as the top five most influential features. Conclusions: Our model showed promising discrimination and calibration in predicting early outcomes of PAE with nBCA glue, highlighting the potential of precision medicine to deliver interpretable, individualized risk assessments.